Brand Reference: Lysteda
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) RxNorm Concept ID | 10691 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $136.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $18.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $22.00 / mo | 22 Zero-PHI Verified Patient Logs |
Occupies the lysine-binding kringle domains of plasminogen, halting fibrin clot dissolution in heavy perimenopausal menorrhagia (650 mg TID x 5d) while at low off-label dermatologic doses (250 mg BID) blocking UV-induced keratinocyte plasmin activation of arachidonic acid, alpha-MSH, and VEGF in refractory dermal melasma.
Out-of-pocket price dispersion on Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) spans $18.20 to $136.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.6400/unit, allowing cash buyers bypassing PBM spread pricing to retain $117.80 each month (87% reduction).
With 2–11 hours terminal residence kinetics and 45% oral (food-independent) bioavailability, Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) undergoes > 95% excreted unchanged via glomerular filtration (zero hepatic cyp) and establishes therapeutic activity over 24 hours menstrual blood-loss drop (-40%); 8–12 weeks melasma clearance.
Standard adult regimens span 250 mg PO BID x 12 weeks (off-label refractory melasma), 1300 mg (two 650 mg tabs) PO TID up to 5 days during menses. Prescribers screen specifically against active or prior venous/arterial thromboembolism; concomitant combined hormonal oral contraceptives (additive thrombosis contraindication); subarachnoid hemorrhage, while community micro-logs most frequently note transient hypomenorrhea (14% of reports), mild abdominal bloating (11% of reports), headache (9% of reports).
Across 22 verified cash-pay logs, Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) achieves a 90.70% Worth-It rating with out-of-pocket spend averaging $22.00/mo versus $136.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 250 mg PO BID x 12 weeks (off-label refractory melasma) for Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol); monthly out-of-pocket dropped to $16.02 compared with $136.00 retail.
Completed 10 weeks on Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) (1300 mg (two 650 mg tabs) PO TID up to 5 days during menses). Zero notable side effects on steady dosing.
Consistent biomarker response on 250 mg PO BID x 12 weeks (off-label refractory melasma) Tranexamic Acid (Cyclic Menorrhagia & Melasma Micro-Protocol) sourced via TeleMed ($21.11/mo cash pay without insurance prior authorization).